Scienza e Tecnologia
Implantica presents the fourth quarter 2021 on February 18 at 15:00 CET
Conference call dial-in:
Webcast:
Speakers:
Nicole Pehrsson , Investor Relations
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm .
The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399, info@fnca.se
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/implantica/r/implantica-presents-the-fourth-quarter-2021-on-february-18-at-15-00-cet,c3505720
The following files are available for download: